Request Demo

Last update 19 Apr 2025

Prochlorperazine

Last update 19 Apr 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

2-Chloro-10-(3-(1-methyl-4-piperazinyl)propyl)-phenothiazine, 2-Chloro-10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazine, 3-Chloro-10-(3-(1-methyl-4-piperazinyl)propyl)phenothiazine

+ [11]

Target

D2 receptor

Action

antagonists

Mechanism

D2 receptor antagonists(Dopamine D2 receptor antagonists)

Therapeutic Areas

Nervous System Diseases

Active Indication-

Inactive Indication

Schizophrenia

Originator Organization

GSK Plc

Active Organization-

Inactive Organization

GlaxoSmithKline, Inc.

Drug Highest PhaseWithdrawn

First Approval Date

United States (26 Jan 1959),

Schizophrenia

Regulation-

Structure/Sequence

Molecular FormulaC20H24ClN3S

InChIKeyWIKYUJGCLQQFNW-UHFFFAOYSA-N

CAS Registry58-38-8

Clinical Trials associated with Prochlorperazine

CTRI/2024/10/075430

/ RecruitingPhase 4

A Multi-Centric, Prospective, Single Arm, Open label Post Marketing Observational Study To Assess The Effectiveness And Safety Of Oral Prochlorperazine In Acute Phase In Patients Diagnosed With Benign Paroxysmal Positional Vertigo (BPPV). - NIL

Start Date10 Nov 2024

Sponsor / Collaborator-

CTRI/2024/08/072429

/ Not yet recruitingPhase 3

An open-label phase III randomized controlled trial comparing metoclopramide, thalidomide, prochlorperazine, and lorazepam for treating breakthrough chemotherapy-induced nausea and vomiting in patients receiving olanzapine as part of antiemetic prophylaxis for highly emetogenic chemotherapy. - Nil

Start Date01 Sep 2024

Sponsor / Collaborator-

ACTRN12624000917538

/ Not yet recruitingPhase 2IIT

Efficacy and safety of cetuximab and prochlorperazine combined for solid organ transplant patients with advanced Cutaneous Squamous Cell Carcinoma: CetPro study

Start Date01 Aug 2024

Sponsor / Collaborator

The University of Queensland

100 Clinical Results associated with Prochlorperazine

100 Translational Medicine associated with Prochlorperazine

100 Patents (Medical) associated with Prochlorperazine

2,287

Literatures (Medical) associated with Prochlorperazine

01 May 2025·AMERICAN JOURNAL OF EMERGENCY MEDICINE

Treatment of headache reduces blood pressure among most patients with migraine and elevated blood pressure

Article

Author: Sharpe, Shellyann ; Friedman, Benjamin W ; Kareff, Hannah ; Gupta, Chiraag

BACKGROUND:

It is unclear whether patients with elevated BP and acute headache require treatment with anti-hypertensive medication, anti-headache medication, or both. We determined the impact of migraine medication on blood pressure and pain scores among emergency department patients with moderate or severe migraine and elevated blood pressure.

METHODS:

This study uses data collected from four emergency department-based migraine clinical trials. Patients were included if they had moderate or severe migraine. Patients received one of the following medications or medication combinations: Metoclopramide + dexamethasone, metoclopramide + methylprednisolone acetate, metoclopramide + diphenhydramine, hydromorphone, or prochlorperazine+ diphenhydramine. Blood pressure and 0-10 pain scores were assessed before medication administration and 1 h later.

RESULTS:

We collected data from 729 patients. 13.3 % (97/729) had moderately elevated BP or worse. Among these patients, we identified an association between change in mean arterial pressure and change in pain (B coefficient=0.04,p=0.01) Among 53 study participants with elevated blood pressure but without a diagnosed history of hypertension, mean arterial pressure change was associated with pain score change (B. Among 44 patients with elevated blood pressure and a history of diagnosed hypertension, there was no association with mean arterial pressure (B coefficient=0.03,p=0.25). Among the 97 patients with moderately elevated blood pressure or worse, 73.2 % (95 %CI, 64.2-82.2 %) experienced an improvement in diastolic blood pressure and 78.4 % (95 %CI, 70.0-86.7) improved systolic blood pressure.

CONCLUSION:

In this analysis of data aggregated from four ED-based migraine studies, improvement in pain and blood pressure was associated among patients with acutely elevated blood pressure but without diagnosed hypertension. Most patients with elevated blood pressure who receive headache medication will experience improvement in their blood pressure over the subsequent hour.

PLAIN LANGUAGE SUMMARY:

Many patients present to emergency departments with headache and high blood pressure. A majority of these patients experienced blood pressure improvements upon treatment of their headache, and those with acutely elevated blood pressure but not diagnosed hypertension demonstrated an association between pain and blood pressure improvements. Instead of administering unnecessary anti-hypertensive medication, this research suggests that in a majority of patients, elevated blood pressure can be managed by treating the headache.

24 Mar 2025·ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Functionalization of Pyridines at the C4 Position via Metalation and Capture

Article

Author: Hsu, Han‐Hsiang ; Sk, Md Raja ; Thomas, Andy A. ; Chen, Cheng‐Chun ; Kang, Seokmin

Abstract:

The functionalization of pyridines at positions remote to the N‐atom remains an outstanding problem in organic synthesis. The inherent challenges associated with overriding the influence of the embedded N‐atom within pyridines was overcome using n‐butylsodium, which provided an avenue to deprotonate and functionalize the C4‐position over traditionally observed addition products that are formed with organolithium bases. In this work, we show that freshly generated 4‐sodiopyrdines could undergo transition metal free alkylation reactions directly with a variety of primary alkyl halides bearing diverse functional groups. In addition, after transmetalation to zinc chloride a simple and efficient Negishi cross‐coupling protocol was formulated for a variety of aromatic and heteroaromatic halides. The robustness of this protocol was demonstrated through the late‐stage installation of 4‐pyridyl fragments into a variety of complex active pharmaceutical ingredients including loratadine and prochlorperazine. Furthermore, through rapid injection NMR investigations, we are able to directly observe the evolution of anionic intermediates and determined that two distinct mechanistic pathways lead to the observed site selectivity: (1) the C4‐H within 2,6‐disubstituted pyridines could be removed directly and (2) the C4 selectivity of unsubstituted pyridine originates from the intermolecular exchange of metalation sites via a thermodynamic pathway.

07 Feb 2025·INTERNATIONAL JOURNAL OF PHARMACY PRACTICE

Nausea and vomiting in pregnancy: a cross-sectional study of community pharmacists in the UK

Article

Author: Alter, Marsha ; Lakhani, Shivali ; Williamson, Catherine ; Payne, Bradley ; Righton, Olivia ; Nana, Melanie ; Chapman, Sarah ; Flynn, Angela C ; Bell, Zoe

Abstract:

Objectives:

To assess the content and frequency of advice community pharmacists (CPs) provide to pregnant women with nausea and vomiting, their confidence in providing advice, and their knowledge of the safety of medication used to manage the condition.

Methods:

An online questionnaire of closed- and open-ended questions was distributed to CPs in the UK in May 2023. Closed-ended questions were analysed quantitatively, and conventional content analysis was utilised for open-ended responses.

Key findings:

One hundred and eighty-one respondents completed the questionnaire, 24 responses were excluded, leaving data from 157 available for analysis. The majority (90.4%) of participants reported having experience in providing advice on nausea and vomiting with varying levels of confidence. Advice provided included using over-the-counter products, lifestyle modifications, reassurance, medication advice, and referring to other healthcare professionals. Knowledge of first-line antiemetics considered safe in pregnancy varied; cyclizine was correctly identified as safe during pregnancy by 57.3%, followed by 37.6% for promethazine and 31.2% for prochlorperazine. Self-reported confidence and having experience providing advice were related to higher medication safety identification rates. Five percent of participants reported previous training on the condition, while 70% reported wanting further education, preferably delivered via an online medium.

Conclusions:

This study showed that although 90% of CPs provide advice on nausea and vomiting in pregnancy, their medication safety knowledge varied. The majority of CPs reported wanting further education that would ensure women could access reliable information and evidence-based advice to optimise management of the condition.

News (Medical) associated with Prochlorperazine

26 Jun 2024

·www.biospace.com

Avenacy Announces Launch of Prochlorperazine Edisylate Injection, USP in the U.S. Market

Represents the Company’s eleventh product launch since inception in October 2023 SCHAUMBURG, Ill.--(BUSINESS WIRE)-- Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Prochlorperazine Edisylate Injection, USP in the United States as a therapeutic generic equivalent for COMPAZINE® as approved by the U.S. Food and Drug Administration. Prochlorperazine Edisylate Injection, USP is indicated to control severe nausea and vomiting and for the treatment of schizophrenia. Prochlorperazine has not been shown effective in the management of behavioral complications in patients with mental retardation. This press release features multimedia. View the full release here: (Photo: Business Wire) Avenacy's Prochlorperazine Edisylate Injection, USP is available in 10 mg/2 mL (5 mg per mL) 10-pack multi-dose vials. In line with Avenacy’s mission to champion patient safety and streamline patient care, Prochlorperazine Edisylate Injection, USP will feature the Company’s highly differentiated packaging and labeling to support accurate medication selection. Avenacy will begin shipping Prochlorperazine Edisylate Injection, USP to wholesale partners this week. The Company is supported by a global network of development and contract manufacturing partners that have undergone successful FDA inspections based on cGMP-standards. Prochlorperazine Edisylate Injection, USP had U.S. sales of approximately $15 million for the twelve months ending in June 2023.1 Warning Increased Mortality in Elderly Patients with Dementia-Related Psychosis Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of seventeen placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear. Prochlorperazine Edisylate Injection, USP is not approved for the treatment of patients with dementia-related psychosis (see WARNINGS). Please see link for Full Prescribing Information including the Boxed Warning. COMPAZINE® is a registered trademark of GlaxoSmithKline. 1Source: IQVIA About Avenacy Avenacy is a U.S.-based specialty pharmaceutical company focused on supplying critical injectable medications used to treat patients in various medically supervised settings, from acute care hospitals to outpatient clinics and physician offices. Through a rigorous and optimized selection process, the Company is building out a pipeline of high-quality FDA approved injectable products in order to ensure a resilient portfolio that can meet the needs of today’s dynamic drug supply chain. With an experienced team, commitment to quality and reliability, and product offerings intended to facilitate safe and efficient patient care, Avenacy strives to be a trusted partner for essential medications. Avenacy was launched in 2023 and is headquartered in Schaumburg, IL. For more information, please visit .

Drug ApprovalClinical Result

06 Jun 2024

·www.drugs.com

Statins, Metformin Can Cut Odds for Brain Aneurysms

THURSDAY, June 6, 2024 -- Common drugs used to control cholesterol, blood sugar and high blood pressure might also lower a person’s risk of stroke , a new study finds. The researchers evaluated the risk of brain aneurysms that cause bleeding strokes in patients. For the study, they looked at the medical records for nearly 4,900 patients who had a bleeding stroke, and compared them against nearly 44,000 people who never had a brain aneurysm. They identified four specific drugs that appeared to lower the risk of a brain aneurysm, after accounting for other risk factors: “We urgently need new ways to prevent this type of stroke, which occurs at younger ages and with a higher death rate than other types of stroke,” said researcher Jos Peter Kanning , with the University Medical Center Utrecht in the Netherlands. “Our current surgical treatments for brain aneurysms have a risk of permanent disability and death that often outweighs the potential benefits, so preventing rupture with a noninvasive drug would be very beneficial,” Kanning added in a university news release. On the other hand, four drugs increased the risk of a bleeding stroke: the blood thinner warfarin , the antidepressant venlafaxine , the antipsychotic prochlorperazine , and the painkiller co-codamol . The findings, which were published June 5 in the journal Neurology, only show an association between these drugs and stroke risk, the researchers noted. “Future research is needed to investigate these associations and determine whether these drugs are effective in reducing the risk of hemorrhagic stroke,” Kanning said. “This work could also help us identify additional risk factors for subarachnoid hemorrhage, potentially leading to new therapies to manage aneurysms.” Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

06 May 2024

·www.prnewswire.com

Neurocrine Biosciences Supports Tardive Dyskinesia Awareness Week by Advocating for Routine Screening and Monitoring

Approximately 600,000 people in the United States live with tardive dyskinesia (TD), and about 65% have not yet been diagnosed1-3 The diagnosis rate can be improved by increasing routine TD screenings in people treated with antipsychotic medication4 SAN DIEGO, May 6, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today renewed its commitment to increasing awareness and advancing care for people living with TD during Tardive Dyskinesia Awareness Week, May 5-11. TD is a persistent, involuntary movement disorder associated with the use of antipsychotic medication that may be necessary to treat individuals living with mental illness, such as bipolar disorder, major depressive disorder, schizophrenia and schizoaffective disorder.1,5-7 For seven consecutive years, TD Awareness Week – which occurs each year during Mental Health Awareness Month – has brought together the mental health advocacy community and states across the country to recognize the approximately 600,000 people in the U.S. living with TD.1,2 This year, Neurocrine is joining participants of TD Awareness Week to conduct initiatives nationwide to decrease stigma, improve recognition and increase routine screenings, diagnosis and awareness of appropriate treatment of TD. "TD Awareness Week increases dialogue around the physical, social and emotional consequences the uncontrollable movements of TD can have on individuals who are trying to manage their mental health," said Josie Cooper, Executive Director of the Movement Disorders Policy Coalition. "It's important that we continue to work together to acknowledge and increase support for people living with TD and to ensure they receive the diagnosis and care they deserve." TD is a chronic condition that is unlikely to improve without treatment.1,4 The uncontrollable movements can affect one's ability to work, drive, walk, button a shirt or eat and drink and cause worry, frustration and self-consciousness.2,8-10 It is critical that people taking antipsychotic medication for mental illness be monitored by a healthcare provider for drug-induced movement disorders, such as TD.4,6 Routine screenings are essential for detection, proper diagnosis and appropriate management to help improve therapeutic outcomes.4 "The majority of people living with TD remain undiagnosed, reinforcing the importance of proactive recognition and treatment of the condition," said Eiry W. Roberts, M.D., Chief Medical Officer, Neurocrine Biosciences. "We are committed to partnering with all stakeholders during TD Awareness Week and beyond to advocate for routine screenings for patients at risk for TD." The Meadows Mental Health Policy Institute, which provides nonpartisan, data-driven and program guidance to improve mental health services, released a recent report, in collaboration with Neurocrine Biosciences, highlighting the importance of measurement-based care (MBC) for people with a serious mental illness who are treated with antipsychotics. MBC involves the systematic use of validated rating scales to assess the effectiveness of treatment and make adjustments as needed to improve outcomes.11 For TD, MBC provides an effective mechanism for earlier detection and the ability to develop and routinely monitor an appropriate treatment plan for patients to help improve outcomes.11 The full report can be accessed at . The 2020 American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia recommends screening for TD at least every six months in high-risk patients and at least every 12 months for others at risk of developing TD.4 To learn more about TD, living with TD and how to treat TD, visit TalkAboutTD.com. About Tardive Dyskinesia Awareness Week Since it began in 2018, all 50 states, Washington, D.C., and various mental health advocacy organizations have recognized the first full week of May as Tardive Dyskinesia (TD) Awareness Week, which acknowledges the approximately 600,000 Americans living with TD, an involuntary movement disorder associated with taking antipsychotic medication commonly prescribed to treat mental illnesses. Participants in TD Awareness Week help to educate people across the United States on the potential physical, social and emotional consequences of TD and the importance of speaking with a healthcare provider about the occurrence and impact of the uncontrollable movements and available treatment options. As part of Neurocrine Biosciences' commitment to TD education, more information is available at Neurocrine.com/TD-Awareness, and resources are available at TalkAboutTD.com. These resources can help patients and care partners understand TD and recognize its symptoms, request support and have a conversation with their healthcare provider about ways to manage their TD, including treatment options. Healthcare professionals can also visit MIND-TD.com to learn about differential diagnosis of TD and other movement disorders. For more information, follow and join the conversation online by sharing #TDAwarenessWeek #Screen4TD. About Tardive Dyskinesia (TD) Tardive dyskinesia (TD) is a movement disorder that is characterized by uncontrollable, abnormal and repetitive movements of the face, torso and/or other body parts, which may be disruptive and negatively impact patients. The condition is associated with taking certain kinds of mental health medicines (antipsychotics) that help control dopamine receptors in the brain. Taking antipsychotics commonly prescribed to treat mental illnesses such as major depressive disorder, bipolar disorder, schizophrenia and schizoaffective disorder, and other prescription medicines (metoclopramide and prochlorperazine) used to treat gastrointestinal disorders are associated with TD. In patients with TD, these treatments are thought to result in irregular dopamine signaling in a region of the brain that controls movement. The symptoms of TD can be severe and are often persistent and irreversible. TD is estimated to affect approximately 600,000 people in the United States. About Neurocrine Biosciences, Inc. Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X (Formerly Twitter) and Facebook. (*in collaboration with AbbVie) NEUROCRINE BIOSCIENCES, NEUROCRINE and YOU DESERVE BRAVE SCIENCE, are registered trademarks of Neurocrine Biosciences, Inc. The Neurocrine logo is a trademark of Neurocrine Biosciences, Inc. References Cloud LJ, Zutshi D, Factor SA. Tardive dyskinesia: therapeutic options for an increasingly common disorder. Neurotherapeutics. 2014;11(1):166-176. doi:10.1007/s13311-013-0222-5 Data on file. Neurocrine Biosciences, Inc. Carbon M, Hsieh CH, Kane JM, Correll CU. Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis. J Clin Psychiatry. 2017;78(3):e264–e278. doi:10.4088/JCP.16r10832 Keepers GA, Fochtmann LJ, Anzia JM, et al. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry. 2020;177(9):868-872. doi:10.1176/appi.ajp.2020.177901 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Text Revision. American Psychiatric Association; 2023. Guy W. ECDEU Assessment Manual for Psychopharmacology. National Institute of Mental Health; 1976. Caroff SN, Hurford I, Lybrand J, Campbell EC. Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial. Neurol Clin. 2011;29(1):127-148. doi:10.1016/j.ncl.2010.10.002 Task Force on Tardive Dyskinesia. Tardive dyskinesia: a task force report of the American Psychiatric Association; 1992. Boumans CE, de Mooij KJ, Koch PA, van 't Hof MA, Zitman FG. Is the social acceptability of psychiatric patients decreased by orofacial dyskinesia? Schizophr Bull. 1994;20(2):339-344. doi:10.1093/schbul/20.2.339 Yassa R. Functional impairment in tardive dyskinesia: medical and psychosocial dimensions. Acta Psychiatr Scand. 1989;80(1):64-67. doi:10.1111/j.1600-0447.1989.tb01301 Increasing measurement-based assessment and care for people with serious mental illness. Meadows Mental Health Policy Institute. Published January 2024. Accessed March 1, 2024. © 2024 Neurocrine Biosciences, Inc. All Rights Reserved. CP-TD-US-1569 05/2024 SOURCE Neurocrine Biosciences, Inc.

100 Deals associated with Prochlorperazine

External Link

KEGG	Wiki	ATC	Drug Bank
D00493	Prochlorperazine	N05AB04	DB00433

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Schizophrenia	United States	GlaxoSmithKline, Inc.	26 Jan 1959

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03185130 (I-FiBH, CTgov)	Phase 4	Headache	58	Prochlorperazine 0.15 mg/kg up to 10 mg IV+Normal Saline 5mL+Diphenhydramine 1 mg/kg up to 50 mg IV (Standard Treatment Arm)	yxlbuffwzt(laqdjeopnw) = whychsnevg yzmgkwceqz (ylrbucwtou, 29.3) View more	-	06 Jun 2024
				Normal Saline 20mL/kg+Prochlorperazine 0.15 mg/kg up to 10 mg IV+Diphenhydramine 1 mg/kg up to 50 mg IV (Study Arm)	yxlbuffwzt(laqdjeopnw) = hojgjlqxls yzmgkwceqz (ylrbucwtou, 31.0) View more
NCT03435003 (CTgov)	Phase 4	Postoperative Nausea and Vomiting \| Vomiting	83	dexmedetomidine+Compazine+Total intravenous anesthesia+Fentanyl+scopolamine transdermal+sugammadex+Reglan+Propofol+Ondansetron+Aprepitant 80 mg Oral Capsule+Dexamethasone (Intervention Arm)	fpdzezuoma = qfahrcuisw pzaveklkap (otvzaetdbp, ozfhiysdmd - zjkapgdyos) View more	-	14 Feb 2024
				Compazine+sugammadex+Reglan+Sevoflurane+Desflurane+Ondansetron+Dexamethasone (Control Arm)	fpdzezuoma = kdmugrpbgz pzaveklkap (otvzaetdbp, rdifdqalgl - qymlvmdscj) View more
CNS2023	Phase 1/2	Migraine Disorders	17	Normal Saline, Prochlorperazine, Ketorolac	anlnghdntw(tyjywrddta) = wakfbsjotk rpmitbynlo (ityikerzvz ) View more	Positive	01 Oct 2023
NCT01629329 (Migraine, CTgov)	Phase 4	Acute migraine	93	Aspirin, Acetaminophen, Caffeine pills (Aspirin, Acetaminophen, Caffeine Pills)	egsuqwofbe(pycpnujslp) = vkwosjqmup khgbqjukqs (esjoqkqzdg, juzpvoznfi - mloookxoxe) View more	-	18 Mar 2020
				Prochlorperazine 10mg (Prochlorperazine 10mg)	egsuqwofbe(pycpnujslp) = sdelihemob khgbqjukqs (esjoqkqzdg, cnzajxtheb - lttdsvktxm) View more
NCT02389829 (CTgov)	Phase 4	Acute migraine	127	Hydromorphone (Hydromorphone)	vjdxnqzpgg = pnwowbwyrv erxkwzsrrm (aumvbowovx, vwoocmnvjq - yznwsrcifn) View more	-	06 Jun 2018
				prochlorperazine+Diphenhydramine (Prochlorperazine)	vjdxnqzpgg = gpwmcbwdiq erxkwzsrrm (aumvbowovx, bqguaygknw - njmjlroqpy) View more
NCT00422812 (CTgov)	Phase 2	Migraine With Aura	400	Inhaled Placebo (Inhaled Placebo)	wrhuydvegh = zgsrwaatmg ijpjbibogk (emswtmfzji, towxbcqfyo - yghkwwbysi) View more	-	25 Jan 2018
				Prochlorperazine+Staccato (Inhaled PCZ 5 mg)	wrhuydvegh = libqvfaqyd ijpjbibogk (emswtmfzji, zisercqjxf - awaltkkpsx) View more
NCT00475085 (CTgov)	Phase 3	Nausea \| Delayed Nausea and Vomiting	1,021	prochlorperazine+placebo+granisetron hydrochloride+Dexamethasone (Arm II)	ldleezzkus(nrpzntyjqn) = zswhavdicz ahnwmhzsub (fqomkpatyo, 1.27) View more	-	03 Nov 2013
				placebo+palonosetron hydrochloride+aprepitant+Dexamethasone (Arm III)	ldleezzkus(nrpzntyjqn) = xcvojcynwo ahnwmhzsub (fqomkpatyo, 1.15) View more
NCT02657031 \| NCT03185130 (Pubmed \| Ann Emerg Med)	Phase 4	Acute migraine	-	IV prochlorperazine with diphenhydramine	bzfykmwywm(wvsjlqivot) = fpbwopfzxk hsczqjompo (srtvwebofx )	Positive	01 Jul 2010
				subcutaneous sumatriptan	bzfykmwywm(wvsjlqivot) = xweueipvkq hsczqjompo (srtvwebofx )
ASCO2010	Not Applicable	Chemotherapy-induced nausea and vomiting	96	Prochlorperazine	vnzhxohimz(fyfeycotaq) = gajnxhcxon krxerdckij (ssedkjayfc )	-	20 May 2010
				5HT3 antagonists	vnzhxohimz(fyfeycotaq) = bqemzvogld krxerdckij (ssedkjayfc )
NCT02657031 \| NCT03185130 (Pubmed \| Ann Emerg Med)	Phase 4	Acute migraine	77	Metoclopramide 20 mg	yvvbndpnnc(emjrgyyqas) = hvetwgyzjo hlwsckltqx (enzbojpfmh )	-	01 Oct 2008

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis